Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online July 27, 2007
Diabetes 56:2485-2493, 2007
DOI: 10.2337/db06-1642
© 2007 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db06-1642v1
db06-1642v2
56/10/2485    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, T.
Right arrow Articles by Levi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, T.
Right arrow Articles by Levi, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy

Tao Jiang1, Xiaoxin X. Wang1, Pnina Scherzer2, Paul Wilson1, James Tallman1, Hideaki Takahashi1, Jinping Li1, Mieko Iwahashi1, Eileen Sutherland1, Lois Arend3, and Moshe Levi1

1 Division of Renal Diseases and Hypertension, Departments of Medicine, Physiology and Biophysics, Denver VA Medical Center and University of Colorado Health Sciences Center, Denver, Colorado
2 Nephrology and Hypertension Services, Hadassah University Hospital, Jerusalem, Israel
3 Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio

Address correspondence and reprint requests to Moshe Levi, MD, Departments of Medicine, Physiology, and Biophysics, Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, 4200 East 9th Ave., Denver, CO 80262. E-mail: moshe.levi{at}uchsc.edu

Abbreviations: ACC, acetyl-CoA carboxylase; FBS, fetal bovine serum; FSP-1, fibroblast specific protein-1; FXR, farnesoid X receptor; HFD, high-fat diet; IL-6, interleukin-6; L-PK, liver-type pyruvate kinase; LFD, low-fat diet; MCP-1, monocyte chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1; PAS, periodic acid Schiff; SCD-1, stearoyl-CoA desaturase-1; SHP, small heterodimer partner; {alpha}-SMA, {alpha}-smooth muscle actin; SREBP, sterol regulatory element–binding protein; TGF-ß, transforming growth factor-ß; TNF-{alpha}, tumor necrosis factor-{alpha}; VEGF, vascular endothelial growth factor


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
OBJECTIVE—Recent studies indicate an important role for nuclear receptors in regulating lipid and carbohydrate metabolism, fibrosis, and inflammation. Farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily. FXR is highly expressed in the liver, intestine, adrenal gland, and kidney. The primary bile acids are the highest affinity endogenous ligands for FXR. The effects of FXR agonists in diabetic kidney disease, the main cause of end-stage renal disease, however, have not been determined.

RESEARCH DESIGN AND METHODS—To identify the effect of FXR activation in modulation of diabetic nephropathy, we treated 1) C57BL/6J mice on low-fat diet or high-fat diet with FXR agonists (GW4064 or cholic acid) for 1 week; 2) C57BLKS/J-db/db mice and their lean mates with GW4064 for 1 week; and 3) C57BL/6J-db/db mice and their lean mates with cholic acid for 12 weeks.

RESULTS—We found that FXR agonists modulate renal sterol regulatory element–binding protein-1 (SREBP-1) expression and lipid metabolism and renal expression of profibrotic growth factors, proinflammatory cytokines, and oxidative stress enzymes and decrease glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria. In renal mesangial cells, overexpression of FXR or treatment with GW4064 also inhibited SREBP-1c and other lipogenic genes, transforming growth factor-ß, and interleukin-6, suggesting a direct role of FXR in modulating renal lipid metabolism and modulation of fibrosis and inflammation.

CONCLUSIONS—These results therefore indicate a new and important role for FXR in the kidney and provide new therapeutic avenues for the treatment of diabetic nephropathy.

Since Virchow (1) first suggested the association between lipids and renal disease in 1858, there is now growing evidence that abnormal lipid metabolism and renal accumulation of lipids play a role in the pathogenesis of diabetic nephropathy. In studies in our laboratory in the streptozotocin, Akita, and OVE26 models of type 1 diabetes (2,3), in diet-induced obesity and insulin resistance (4), in the FVB-db/db model of type 2 diabetes (5), and in aging mice (6,7), we have found increased renal expression of the transcriptional factor, the sterol regulatory element–binding protein-1 (SREBP-1), which results in increased renal synthesis and accumulation of triglycerides and correlates with increased expression of profibrotic growth factors, mesangial expansion, podocyte injury, glomerular and tubulointerstitial accumulation of extracellular matrix proteins, and proteinuria.

Whether the accumulation of lipids per se may mediate diabetic renal disease is demonstrated in SREBP-1a transgenic mice that overexpress SREBP-1a in the kidney. In the absence of hyperglycemia or dyslipidemia, increased expression of SREBP-1a in the kidney causes lipid accumulation and increased expression of transforming growth factor-ß (TGF-ß), plasminogen activator inhibitor (PAI)-1, and vascular endothelial growth factor (VEGF), resulting in renal hypertrophy, accumulation of extracellular matrix proteins, mesangial expansion, glomerulosclerosis, and proteinuria (2). In contrast, in SREBP-1c knockout mice, high saturated–fat diet–induced increase in renal expression of TGF-ß, PAI-1, and VEGF and the extracellular matrix proteins type IV collagen and fibronectin are prevented (4). These studies therefore imply that alterations in renal lipid metabolism mediated by SREBP-1 play an important role in the pathogenesis and progression of renal disease in type 1 diabetes, obesity and insulin resistance, type 2 diabetes, and aging.

Recently, the farnesoid X receptor (FXR), a ligand-activated transcription factor and a member of the nuclear receptor superfamily, which plays an important role in regulation of bile acid metabolism (8,9), has in addition been shown to play an important role in the regulation of fatty acid metabolism in the liver by inhibiting SREBP-1 (10,11). FXR is also involved in the regulation of carbohydrate metabolism, including inhibition of gluconeogenesis (12–15). In addition, in the liver, FXR agonists have been shown to prevent fibrosis in part by inhibiting TGF-ß expression and activity (16,17).

FXR is also expressed in the kidney (18–20); however, the potential role of FXR agonists in regulating renal lipid metabolism or modulating renal disease has not been determined.

The purpose of this study was to determine the role of FXR activation 1) in regulating renal SREBP-1c expression, 2) in modulating glomerulosclerosis and proteinuria in the Leprdb/db (db/db) model of obesity and type 2 diabetes, and 3) in preventing high glucose–induced alterations in lipid metabolism and increased expression of profibrotic growth factors and proinflammatory cytokines in renal glomerular mesangial cells.

The results indicate that treatment of C57BL/6J mice with FXR agonists prevent the high fat–induced increase of the renal expression of SREBP-1. In addition, treatment of db/db mice with FXR agonists prevents the progression of proteinuria and glomerulosclerosis, the renal accumulation of triglycerides, and the increased expression of profibrotic growth factors, proinflammatory cytokines, and NADPH oxidase. Furthermore, cell culture studies indicate that in the presence of a high-glucose milieu FXR plays a direct role in inhibiting SREBP-1–mediated fatty acid synthesis and expression of profibrotic growth factors and proinflammatory cytokines.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Male C57BL/6J mice were obtained from The Jackson Laboratories (Bar Harbor, ME). They were maintained on a 12-h light/dark cycle and fed a control low-fat 10 kcal% fat diet (LFD; D12450B) or a high-fat 60 kcal% saturated (lard) fat diet (HFD; D12492) obtained from Research Diets (New Brunswick, NJ) for 1 week with the treatment of 1) vehicle only; 2) the synthetic FXR ligand GW4064 (21), 30 mg/kg body wt i.p. injection, twice daily; or 3) the natural FXR ligand cholic acid 0.5% wt/wt in diet.

Male Leprdb/db mice with type 2 diabetes and their nondiabetic control Leprdb/m mice on the C57BL/6J or C57BLKS/J genetic background were obtained from The Jackson Laboratories. C57BLKS/J-db/db and the same background nondiabetic mice were treated with GW4064 or vehicle only (40% 2-hydroxypropyl-ß-cyclodextrin; Sigma) via intraperitoneal injection (same dose as above) for 1 week. The C57BL/6J-db/db and control mice were fed with control diet only (D12450B; Research Diets) or control diet supplemented with cholic acid 0.5% wt/wt for 12 weeks.

The animal studies and the protocols were approved by the institutional review boards at the Denver VA Medical Center and the University of Colorado Health Sciences Center.

Blood and urine chemistries.
Blood glucose levels were measured by means of a Glucometer Elite XL (Bayer, Tarrytown, NY). Plasma triglyceride and total cholesterol were measured with kits from Wako Chemical (Richmond, VA). Urine albumin and creatinine concentrations were determined using kits from Exocell (Philadelphia, PA). Results were expressed as the urine albumin-to-creatinine ratio (milligrams per milligram).

Isolation of glomeruli and proximal tubules.
The renal cortex was separated from the medulla and cut into small fragments under sterile conditions. Glomeruli were isolated by differential sieving based on the report of Harper et al. (22). The purity of glomeruli was checked by light microscopy to ensure that they were >99% free of any tubular tissue. Proximal tubules were isolated according to the method of Brezniceanu et al. (23) by use of the Percoll gradient. Proximal tubular cells were characterized by their histological appearance as described previously (24). This procedure yielded a highly purified preparation of proximal tubules (>97% by microscopy).

RNA extraction and quantitative real-time PCR.
Total RNA was isolated from the kidneys using SV total RNA isolation system from Promega (Madison, WI), and cDNA was synthesized using reverse transcript reagents from Bio-Rad Laboratories (Hercules, CA). The mRNA level was quantified using Bio-Rad iCyCler real-time PCR machine. Cyclophilin was used as internal control, and the amount of RNA was calculated by the comparative threshold cycle (CT) method as recommended by the manufacturer. All the data were calculated from triplicate reactions. Primer sequences used have been described previously (3) or are available from the authors upon request.

Nuclei isolation.
Kidneys were homogenized at 4°C in homogenization buffer (20 mmol/l Tris-Cl, pH 7.4, 75 mmol/l NaCl, 2 mmol/l EGTA, 2 mmol/l EDTA, 1 mmol/l Na3VO4, and 1 mmol/l dithiothreitol) supplemented with a protease inhibitor cocktail consisting of 104 mmol/l AEBSF [4-(2-aminocthyl)-benzenesulfonyl fluoride], 0.08 mmol/l aprotinin, 2 mmol/l leupeptin, 4 mmol/l bestatin, 1.5 mmol/l pepstatin A, and 1.4 mmol/l E-64 (Sigma-Aldrich, St. Louis, MO). Nuclear extracts were prepared as we have previously described (4–7).

Protein electrophoresis and Western blotting.
Equal amount of protein samples were subjected to SDS-PAGE (10% wt/vol), and they were then transferred to nitrocellulose membranes. After blocking with 5% fat-free milk powder with 1% Triton X-100 in Tris-buffered saline (20 mmol/l Tris-Cl and 150 mmol/l NaCl, pH 7.4), the blots were incubated with antibody against SREBP-1 (SC-8984; 1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA). Corresponding secondary antibody was visualized using enhanced chemiluminescence (Pierce, Bradford, IL). The signals were quantified with a Phosphor Imager with chemiluminescence detector and the accompanying densitometry software (Bio-Rad).

Lipid extraction and measurement of lipid composition.
Lipids from the kidneys were extracted by the method of Bligh and Dyer, as we have previously described (4–7). Triglyceride and cholesterol content was measured using kits from Wako Chemicals.

Periodic acid Schiff staining and immunofluorescence microscopy.
Mice were anesthetized and perfused as previously described (4–7). Paraffin sections were stained for periodic acid Schiff (PAS) and imaged with an Olympus microscope. Frozen sections were used for immunostaining of fibronectin and imaged with a laser scanning confocal microscope (Zeiss LSM 510).

Cell culture.
Mouse mesangial cell line was obtained from the American Type Culture Collection (Manassas, VA). The cells were maintained in Dulbecco's modified Eagle's medium/F12 containing 5% fetal bovine serum (FBS), 100 µg/ml streptomycin, 100 units/ml penicillin, and 4 mmol/l glutamine, with a normal D-glucose concentration of 100 mg/dl. The cells were incubated in a humidified atmosphere of 5% CO2 at 37°C and passed every 3 days by trypsinization. For FXR overexpression experiments, mouse mesangial cells were transfected with pCMX-mFXR or empty pCMX vector (provided by Dr. David Mangelsdorf) in the medium containing 5% FBS with or without GW4064 and harvested 24 h after transfection for mRNA quantitative analysis and nuclei extraction as described above or previously (4–7). For FXR agonist treatment, cells at 80% confluence were made quiescent by incubation overnight with medium in 0.2% FBS and then treated for 48 h with different conditions as described in the figure legends.

Statistical analysis.
Results are presented as the means ± SE for at least three independent experiments. Data were analyzed by ANOVA and Student-Newman-Keuls tests for multiple comparisons or by Student's t test for unpaired data between two groups. Statistical significance was accepted at the P < 0.05 level.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
FXR and SREBPs coexist in the glomeruli and proximal tubule cells.
To examine the localization of FXR in the kidney, we isolated glomeruli and proximal tubules from mouse kidney. Real-time PCR detected the expression of FXR, SREBP-1c, and SREBP-2 transcripts in both glomeruli and proximal tubules to a significant extent. The expression levels in glomeruli were 30% of those in proximal tubule cells for both FXR and SREBP-1c and 45% for SREBP-2 (Table 1). The relative mRNA level of glomeruli marker podocin and proximal tubule marker NaPi IIa confirmed the purity of isolated fragments. In addition, we observed mRNA expression of FXR and SREBP-1c by real-time PCR in both cultured mouse mesangial cell line and podocyte cell line.


View this table:
[in this window]
[in a new window]

  		TABLE 1 mRNA expression of FXR and SREBPs in glomeruli and proximal tubules

 
Treatment of mice with the GW4064 or cholic acid causes upregulation of small heterodimer partner (SHP) and downregulation of SREBP-1 and prevents the HFD-induced increase in SREBP-1 expression.
To determine the role of FXR activation on renal SREBP-1 regulation, C57BL/6J mice were fed the LFD or HFD with the FXR agonists for 1 week. In LFD-fed mice, treatment with the FXR agonist GW4064 or natural ligand cholic acid induced upregulation of the SHP, a well-characterized FXR target gene (9), and caused downregulation of SREBP-1c mRNA, a master regulator of lipogenic genes in the kidney (Fig. 1). Furthermore, in agreement with our published results (4), HFD induced increased expression of renal SREBP-1, which was prevented by the treatment with GW4064 or cholic acid (Fig. 1).


Figure 1
View larger version (17K):
[in this window]
[in a new window]

  		FIG. 1. C57BL/6J mice were fed with LFD or HFD in the presence and absence of treatment with GW4064 or cholic acid (CA) (n = 6 in each group). RNA was extracted from the kidneys. SHP and SREBP-1c mRNA abundance was determined by real-time quantitative PCR. Nuclear SREBP-1 protein abundance was analyzed by Western blotting. A: GW4064 and CA induced a significant increase in FXR target gene SHP mRNA level in the kidneys of LFD-treated mice. B: GW4064 and CA induced a significant decrease in renal SREBP-1c mRNA level in LFD-treated mice. HFD induced upregulation of renal SREBP-1c mRNA level. This effect was prevented by supplementation of HFD with GW4064 or CA as indicated by significant decreases in SREBP-1c mRNA level. C: GW4064 prevented the HFD-induced SREBP-1 nuclear protein level. *P < 0.05 vs. LFD; #P < 0.05 vs. HFD.

 
Short-term treatment of db/db mice with GW4064 regulates the renal gene expression.
The above data demonstrating that FXR agonists modulate renal SREBP-1 expression in HFD-fed C57BL/6 mice prompted us to examine the function of FXR in a diabetic mouse model. The db/db mice have been extensively used as model of obesity and type 2 diabetes. To investigate how FXR activation impacts the renal gene expression in an acute way, we performed 1-week treatment with FXR agonist GW4064 in 7-week-old C57BLKS/J-db/db mice when severe hyperglycemia had developed. Administering GW4064 had no significant effect on ad libitum (Table 2) or 16-h fasting (data not shown) blood glucose concentrations in control and db/db mice after a 1-week treatment. Furthermore, GW4064 treatment did not change the circulating triglyceride level. However, plasma total cholesterol concentration was significantly decreased in the treated mice.


View this table:
[in this window]
[in a new window]

  		TABLE 2 Effects of 1 week GW4064 treatment in C57BLKS/J db/db mice

 
Dysregulation of renal lipid metabolism has been shown to play an important role in the pathogenesis of diabetic nephropathy. In agreement with an earlier study on FVB-db/db mice (5), we found increased renal expression of SREBP-1c mRNA and its target enzyme stearoyl-CoA desaturase-1 (SCD-1) in C57BLKS/J-db/db mice. Treatment with the FXR agonist significantly attenuated the increased expression of SREBP-1c and SCD-1 mRNA in the kidneys of db/db mice (Table 2).

In diabetic kidney diseases, glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria were associated with increased renal expression of 1) mesangial matrix proteins (e.g., fibronectin), 2) fibrosis markers fibroblast-specific protein-1 (FSP-1) and {alpha}-smooth muscle actin ({alpha}-SMA), 3) the profibrotic growth factors (e.g., TGF-ß and PAI-1), 4) the proinflammatory cytokines tumor necrosis factor-{alpha} (TNF-{alpha}) and monocyte chemoattractant protein-1 (MCP-1), and 5) the NADPH oxidase system (e.g., Nox2). The significant increase in the renal mRNA expression of genes involved in those pathways has been noted in 8-week-old untreated C57BLKS/J-db/db mice (Table 2). Treatment with GW4064 prevented or significantly attenuated the increases in mesangial matrix protein, profibrotic growth factors, and pro-inflammatory and pro-oxidative factors in db/db mice, indicating a renal-protective role for FXR activation.

Chronic treatment of db/db mice with cholic acid improves diabetic renal disease.
Because cholic acid diet lowered blood glucose level significantly in our own observation on C57BLKS/J-db/db mice after 1 week of treatment (530.7 ± 29 before vs. 211.5 ± 14.1 mg/dl after, P < 0.01) and based on another report (14), we used C57BL/6J-db/db mice for our long-term treatment. This strain develops a moderate hyperglycemia and exhibits a remission from hyperglycemia after 12 weeks of age (25). In this regard, this would allow us to determine the effects of cholic acid independent of major changes in serum glucose.

We treated db/db mice with cholic acid at 16 weeks of age when they have already developed proteinuria and mesangial expansion to determine whether treatment with cholic acid is able to prevent the progression of diabetic kidney disease. After 12 weeks of db/db mice receiving control diet (that is diet without cholic acid), there was clear evidence of renal injury (Fig. 2) despite the normalization of blood glucose levels (Table 3). However, cholic acid caused significant decreases in proteinuria (Table 3) and glomerulosclerosis as determined by PAS staining (Fig. 2A–D) and immunofluorescence microscopy for fibronectin, a major mesangial matrix protein (Fig. 2E–H). Consistent with the immunofluorescence imaging, cholic acid also prevented the increase in renal fibronectin mRNA level in db/db mice (Table 3). In addition, cholic acid significantly attenuated the increase in renal mRNA expression of FSP-1 and {alpha}-SMA in db/db mice, both upregulated during development of tubulointerstitial fibrosis (26,27) (Table 3).


Figure 2
View larger version (88K):
[in this window]
[in a new window]

  		FIG. 2. PAS staining of kidney sections (A–D) and immunofluorescence microscopy of kidney sections for fibronectin (E–H). A and E: db/m. B and F: db/db. C and G: db/m with cholic acid. D and H: db/db with cholic acid. Mesangial expansion and increased fibronectin accumulation in db/db mice are prevented by treatment with cholic acid. (Please see http://dx.doi.org/10.2337/db06-1642 for a high-quality digital representation of this figure.)

 

View this table:
[in this window]
[in a new window]

  		TABLE 3 Effects of 12 weeks’ cholic acid treatment in C57BL/6J db/db mice

 
Treatment with cholic acid also downregulated the expression of SREBP-1c and SCD-1 mRNA in the kidneys of db/db mice (Table 3). This was accompanied by a significant decrease in renal triglyceride and cholesterol content (Table 3).

Consistent with the observations following short-term treatment with GW4064, cholic acid also decreased the renal expression of several key genes in profibrotic growth factors, proinflammatory cytokines, and oxidative stress enzymes, whose higher expressions are relevant to the pathogenesis of diabetic kidney disease (Table 3).

Overexpression of FXR in mouse mesangial cells induces downregulation of SREBP-1c.
To determine whether FXR can directly modulate renal gene expression, we overexpressed FXR in mouse mesangial cells by transfection with the expression plasmid construct pCMX-mFXR. We found that adding GW4064 alone extremely upregulated the expression of FXR target gene SHP and decreased the SREBP-1c mRNA level (Fig. 3), indicating that there was enough active endogenous FXR in mesangial cells. Overexpression of FXR without adding GW4064 also increases SHP expression, although in a much lower level, but causes a greater decrease in SREBP-1c when compared with GW4064 alone. The activation of FXR without exogenous GW4064 is believed to be mediated by the presence of bile acid in the serum added to the medium. Furthermore, adding GW4064 in the medium of transfected cells does not cause a further decrease in SREBP-1c inhibition but induces marked stimulation of SHP expression compared with FXR overexpression or GW4064 treatment of untransfected cells.


Figure 3
View larger version (17K):
[in this window]
[in a new window]

  		FIG. 3. Mouse mesangial cells were transfected with FXR plasmid (FXR overexpression) or an empty vector (Control) with or without GW4064. Twenty-four hours later, the nuclei were isolated, and nuclear FXR protein abundance was determined by Western blotting (A). RNA was also extracted for SHP (B) and SREBP-1c (C) mRNA level quantitation by quantitative PCR. Overexpression of FXR and GW4064 treatment increased SHP mRNA level but decreased SREBP-1 expression. The representative results are from three independent experiments. *P < 0.05 as specifically indicated.

 
Treatment of mouse mesangial cells with the FXR agonist GW4064 prevents high glucose–induced increases in fatty acid synthesis and increased expression of TGF-ß and interleukin-6.
To further determine whether FXR plays a direct role in regulating renal gene expression in the presence of a diabetic milieu, we examined the effects of the FXR agonist GW4064 in mouse mesangial cells grown in the presence of high glucose (250 or 450 mg/dl D-glucose). We found that a high glucose medium induced dramatic increase of FXR expression and that GW4064 further increased FXR expression (Fig. 4). High glucose also increased FXR target gene SHP expression, but the major upregulation was only seen in the presence of GW4064. In addition, whereas there were glucose-dependent increases in the expression of lipogenic genes, acetyl-CoA carboxylase (ACC) and liver-type pyruvate kinase (L-PK), and in expression of profibrotic growth factor TGF-ß and proinflammatory cytokine interleukin-6 (IL-6), GW4064 prevented the gene induction by high-glucose condition, similar to renal protective role of GW4064 or cholic acid in db/db mice. Equimolar concentration of L-glucose had no effects on gene expression modulation, indicating that the effects of glucose are not mediated by increases in osmolality per se. Cell viability assay (G1780; Promega) showed that the effects of GW4064 treatment were not a result of cytotoxicity (data not shown).


Figure 4
View larger version (34K):
[in this window]
[in a new window]

  		FIG. 4. Subconfluent mouse mesangial cells were exposed to 100 mg/dl D-glucose, 250 mg/dl D-glucose with and without 2.5 µmol/l GW4064, 450 mg/dl D-glucose with and without 2.5 µmol/l GW4064, or osmotic controls (100 mg/dl D-glucose with 150 or 350 mg/dl L-glucose) for 48 h. Cell lysates were used for RNA extraction and subsequent quantitative PCR analysis of mRNA level of FXR (A), SHP (B), ACC (C), L-PK (D), TGF-ß (E), and IL-6 (F). *P < 0.05 vs. D-glucose (100 mg/dl). #P < 0.05 vs. D-glucose (250 or 450 mg/dl) as specifically indicated. High glucose causes increase of FXR and SHP expression, and GW4064 enhanced this effect. ACC, L-PK, TGF-ß, and IL-6 mRNA expressions were increased by high glucose in mouse mesangial cells, an effect that was normalized on treatment with GW4064. The representative results are from three independent experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
There are well-established changes in renal function and structure in diabetes, including mesangial expansion and podocyte injury and loss, resulting in glomerulosclerosis, tubulointerstitial fibrosis, proteinuria, and a decline in glomerular filtration rate (28–33). Several hormonal and metabolic factors, including angiotensin II, TGF-ß, VEGF, proinflammatory cytokines, oxidative stress, and advanced glycation end products, have been shown to modulate diabetes-related renal disease (34,35). In addition, renal accumulation of lipids has also been proposed to play a role in the pathogenesis of diabetic nephropathy (1–7). Moreover, we were able to demonstrate that increased renal expression of SREBP-1 is the key factor linking increased fatty acid synthesis and accumulation of lipids to development of nephropathy (2).

FXR is a member of the nuclear hormone receptor superfamily. High expression of FXR is restricted to liver, intestine, adrenal gland, and kidney. The primary bile acids, chenodeoxycholic acid and cholic acid, are the highest affinity endogenous activating ligands for FXR. In the enterohepatic system, FXR activation plays an important role in maintaining glucose, lipid, and bile acid homeostasis (36,37). In addition, FXR agonists prevent liver fibrosis (17,38).

The kidney has been implicated in both reabsorption and secretion of bile acids (39). However, the role of FXR activation in regulation of renal metabolism and prevention of diabetic nephropathy has not been determined.

The novel finding of our study is that we have determined that treatment with FXR agonists prevents the HFD-induced increases in renal expression of SREBP-1, the major factor leading to lipid accumulation during development of nephropathy. In the db/db model of mice with type 2 diabetes, we have further determined that in addition to modulating renal lipid metabolism, FXR agonists also regulate the renal expression of profibrotic growth factors, proinflammatory cytokines, and oxidative stress enzymes, while decreasing glomerulosclerosis and proteinuria.

Previous studies in our laboratory have associated decreased expression of FXR and its target SHP in the kidneys with a significant increase in renal SREBP-1 mRNA abundance in mouse models of type 1 diabetes (3). Those data suggest a potential negative regulation of SREBP-1–mediated renal lipid metabolism by highly regulated FXR in the kidney. In the current study, we provide further evidence to show that FXR activation by administration of FXR agonists can prevent the increase in renal SREBP-1 expression and activity in HFD-fed mice, a model of diet-induced obesity and insulin resistance (40). Treatment of db/db mice with GW4064 or cholic acid also causes decreases in renal SREBP-1 and SCD-1 expression, and long-term cholic acid treatment prevents the diabetes-associated increases in renal triglyceride and cholesterol content. These effects of FXR are similar to its action in the liver, where it has been shown to modulate fatty acid and triglyceride synthesis in part by decreasing the expression of SREBP-1 (10,11). The molecular basis for FXR to regulate SREBP-1 remains elusive. The FXR-SHP-SREBP-1c regulatory cascade has been proposed to link FXR activity to triglyceride levels in liver and serum (10). Our data in the kidney also support this pathway but do not rule out the possibility that renal lipid accumulation in diabetic nephropathy results from multiple changes in both synthetic and catabolic pathways (41). However, in mesangial cell culture studies, we found that increased expression of SHP was not necessarily leading to reduced SREBP-1c expression. Increased molecular expression of FXR caused a larger decrease in SREBP-1c expression than activation of constitutive level of FXR by GW4064, whereas FXR activation by GW4064 induced a higher increase in SHP mRNA expression. In addition, in high glucose–treated cells, mRNA expression of FXR, SHP, and SREBP-1c was increased (Fig. 4) (2). It is worth noting that the acute effects observed in cultured cells are not always consistent with the in vivo models (12).

Administration of FXR agonists may have systemic effects, including modulating serum glucose and lipids, and metabolic pathways in a number of relevant organs, including the liver, pancreas, muscle, and adipose tissue. In our experiments, GW4064 failed to show hypoglycemic effect on db/db mice, in contrast with the previous study (13). We think the use of animals of different ages and administration of compound in both studies makes a difference. In this regard, it has been shown that GW4064 had no effect on plasma glucose level in ob/ob mice (42). On the other hand, the renal effects of cholic acid treatment were obtained in the mice without hyperglycemia. Therefore, our data suggested that FXR exerts its protective role independently of blood glucose changes. Both GW4064 and cholic acid were found to lower the plasma cholesterol level in db/db mice. How the serum lipid affects the renal pathology is not fully understood. Considering the ability of renal de novo lipid synthesis and its role in diabetic nephropathy, the hypolipidemic effect of FXR agonists may conceivably share the common mechanism with the effect of cholic acid on lowering renal lipid content in db/db mice. The direct renal effect for FXR was also manifested by the cell culture studies. In high glucose–treated renal mesangial cells, FXR activation by GW4064 prevented glucose-induced lipogenic gene expression. Overexpression of FXR or treatment with GW4064 in normal glucose condition repressed the SREBP-1c expression. These data indicate that FXR exerts direct action on the modulation of renal lipid metabolism.

Treatment of db/db mice with cholic acid for 12 weeks significantly improved glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria. The relevant renal gene regulation was also observed in acute treatment of db/db mice with GW4064. Both GW4064 and cholic acid have been shown to have FXR-specific effects from studies in FXR-null mice (13,14,43). However, cholic acid can activate genes by FXR-independent pathways (44,45). Further studies will clarify FXR-dependent and -independent mechanisms by which cholic acid protects against renal injury.

The potential mechanisms for the renal protective effects of FXR include 1) decrease in renal lipid accumulation, 2) decrease in the expression of profibrotic growth factors, 3) decrease in the expression of proinflammatory cytokines, and 4) decrease in oxidative stress. Although FXR agonists have also been shown to modulate hepatic fibrosis, their potential anti-inflammatory and anti-oxidative effects have not been previously reported.

Activation of hepatic stellate cells is thought to mediate the process of liver fibrosis through secretion of extracellular matrix proteins, and activation of FXR reduces the secretion of extracellular matrix proteins by these cells (38). In rat models of extrahepatic and intrahepatic cholestasis, the FXR agonist GW4064 protects against cholestatic liver damage in part by decreasing the expression of TGF-ß (16). Our results, therefore, consistently indicate that in the db/db model of diabetic nephropathy, treatment with the FXR agonist causes decreased expression of 1) profibrotic growth factors TGF-ß, CTGF, and PAI-1; 2) FSP-1; 3) {alpha}-SMA; and 4) fibronectin. FXR agonist treatment also decreased TGF-ß expression in renal mesangial cell culture. These effects of FXR are associated with prevention of renal fibrosis.

Although diabetic nephropathy has not been considered to be an immune-mediated renal disorder, an inflammatory mechanism has been suggested to play a role in the development of diabetic nephropathy (35,46). Anti-inflammatory agents, such as mycophenolate mofetil, prevent the development of glomerular injury in streptozotocin-induced diabetic rats (47). Urinary MCP-1 excretion increases in patients with early diabetic nephropathy, and acute-phase markers of inflammation are associated with diabetic kidney disease in patients with type 2 diabetes (48,49). In this study, we found that FXR agonist treatment downregulated many of the genes that are involved in the inflammatory process, such as TNF-{alpha}, IL-6, and MCP-1, in db/db mice. The same effect was also observed for IL-6 after FXR agonist treatment of mesangial cells grown in the presence of high glucose to mimic the diabetic environment. The mechanisms by which FXR activation regulate the proinflammatory cytokines are not as well understood. However, it is interesting that proinflammatory cytokines can also induce downregulation of nuclear receptors such as FXR during infection and inflammation, accompanied by abnormalities in lipid metabolism that are similar to those that occur in many common disorders, such as diabetes, obesity, and metabolic syndrome (50,51).

In summary, our findings in this study with FXR agonists identify the effect of FXR activation on the prevention of diabetic nephropathy and potential metabolic pathways that may mediate the diabetes-related alterations in renal lipid metabolism, fibrosis, inflammation, and oxidative stress (Fig. 5). These results therefore indicate that 1) long-term treatment of animals with FXR agonists is possible and 2) treatment of diabetic mice with FXR agonists prevents or significantly attenuates the development of mesangial expansion, accumulation of extracellular matrix proteins, and proteinuria at least in part by inhibiting fatty acid synthesis and the expression of profibrotic growth factors, proinflammatory cytokines, and NADPH oxidase in the kidney. This new mechanistic perspective may lead to important new therapeutic considerations and new therapeutic goals for the treatment of diabetic nephropathy.


Figure 5
View larger version (11K):
[in this window]
[in a new window]

  		FIG. 5. A summary of our findings in the db/db mice, indicating that FXR activation may negatively regulate diabetes-related alterations in renal lipid metabolism, expression of profibrotic growth factors and proinflammatory cytokines, and oxidative stress, improving renal fibrosis and proteinuria and preventing diabetic kidney disease.

 


   ACKNOWLEDGMENTS
 
This study was supported by grants from the Juvenile Diabetes Research Foundation, the American Heart Association, the National Institutes of Health (R01-DK-062209 and R01-AG-026529), and VA Merit Review (to M.L.).

We thank Prof. David Mangelsdorf (University of Texas Southwestern Medical Center, Dallas) for providing us with pCMX-mFXR or empty pCMX vector and Timothy M. Willson, Patrick R. Maloney, and Jim L. Collins (Discovery Research GlaxoSmithKline) for providing us with GW4064.


   FOOTNOTES
 
Published ahead of print at http://diabetes.diabetesjournals.org on 27 July 2007. DOI: 10.2337/db06-1642.

T.J. and X.X.W. contributed equally to this work.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication November 22, 2006 and accepted in revised form July 20, 2007


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Virchow R: Cellular Pathology, as Based Upon Physiological and Pathological Histology. 2nd ed. Chance R, Trans. New York, Robert M. Dewitt, 1860, p.383–408
  2. Sun L, Halaihel N, Zhang W, et al.: Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277:18919–18927, 2002[Abstract/Free Full Text]
  3. Proctor G, Jiang T, Iwahashi M, et al.: Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55:2502–2509, 2006[Abstract/Free Full Text]
  4. Jiang T, Wang Z, Proctor G, et al.: Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280:32317–32325, 2005[Abstract/Free Full Text]
  5. Wang Z, Jiang T, Li J, et al.: Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54:2328–2335, 2005[Abstract/Free Full Text]
  6. Jiang T, Liebman SE, Lucia MS, et al.: Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int 68:2608–2620, 2005[Medline]
  7. Jiang T, Liebman SE, Lucia MS, et al.: Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J Am Soc Nephrol 16:2385–2394, 2005[Abstract/Free Full Text]
  8. Makishima M, Okamoto AY, Repa JJ, et al.: Identification of a nuclear receptor for bile acids. Science 284:1362–1365, 1999[Abstract/Free Full Text]
  9. Goodwin B, Jones SA, Price RR, et al.: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517–526, 2000[Medline]
  10. Watanabe M, Houten SM, Wang L, et al.: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113:1408–1418, 2004[Medline]
  11. Zhang Y, Castellani LW, Sinal CJ, et al.: Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18:157–169, 2004[Abstract/Free Full Text]
  12. Duran-Sandoval D, Mautino G, Martin G, et al.: Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53:890–898, 2004[Abstract/Free Full Text]
  13. Zhang Y, Lee FY, Barrera G, et al.: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103:1006–1011, 2006[Abstract/Free Full Text]
  14. Ma K, Saha PK, Chan L, et al.: Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116:1102–1109, 2006[Medline]
  15. Stayrook KR, Bramlett KS, Savkur RS, et al.: Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146:984–991, 2005[Abstract/Free Full Text]
  16. Liu Y, Binz J, Numerick MJ, et al.: Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678–1687, 2003[Medline]
  17. Fiorucci S, Rizzo G, Antonelli E, et al.: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 315:58–68, 2005[Abstract/Free Full Text]
  18. Zhang Y, Kast-Woelbern HR, Edwards PA: Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 278:104–110, 2003[Abstract/Free Full Text]
  19. Suh JM, Yu CT, Tang K, et al.: The expression profiles of nuclear receptors in the developing and adult kidney. Mol Endocrinol 20:3412–3420, 2006[Abstract/Free Full Text]
  20. Bookout AL, Jeong Y, Downes M, et al.: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789–799, 2006[Medline]
  21. Maloney PR, Parks DJ, Haffner CD, et al.: Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43:2971–2974, 2000[Medline]
  22. Harper PA, Robinson JM, Hoover RL, et al.: Improved methods for culturing rat glomerular cells. Kidney Int 26:875–880, 1984[Medline]
  23. Brezniceanu ML, Wei CC, Zhang SL, et al.: Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int 69:1977–1985, 2006[Medline]
  24. Vinay P, Gougoux A, Lemieux G: Isolation of a pure suspension of rat proximal tubules. Am J Physiol 241:F403–F411, 1981[Medline]
  25. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284:F1138–F1144, 2003[Abstract/Free Full Text]
  26. Iwano M, Plieth D, Danoff TM, et al.: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110:341–350, 2002[Medline]
  27. Boukhalfa G, Desmouliere A, Rondeau E, et al.: Relationship between alpha-smooth muscle actin expression and fibrotic changes in human kidney. Exp Nephrol 4:241–247, 1996[Medline]
  28. Mauer SM, Steffes MW, Ellis EN, et al.: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143–1155, 1984[Medline]
  29. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al.: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342–348, 1997[Medline]
  30. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54:1626–1634, 2005[Abstract/Free Full Text]
  31. Petermann AT, Pippin J, Krofft R, et al.: Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 98:e114–e123, 2004[Medline]
  32. Susztak K, Raff AC, Schiffer M, et al.: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233, 2006[Abstract/Free Full Text]
  33. Nakamura T, Kawagoe Y, Ogawa H, et al.: Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis 45:48–53, 2005
  34. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625, 2005[Free Full Text]
  35. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 115:1111–1119, 2005[Medline]
  36. Kalaany NY, Mangelsdorf DJ: LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159–191, 2006[Medline]
  37. Lee FY, Lee H, Hubbert ML, et al.: FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31:572–580, 2006[Medline]
  38. Fiorucci S, Rizzo G, Antonelli E, et al.: A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314:584–595, 2005[Abstract/Free Full Text]
  39. St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, et al.: Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol 204:1673–1686, 2001[Abstract]
  40. Winzell MS, Ahren B: The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 (Suppl. 3):S215–S219, 2004
  41. Johnson AC, Stahl A, Zager RA: Triglyceride accumulation in injured renal tubular cells: alterations in both synthetic and catabolic pathways. Kidney Int 67:2196–2209, 2005[Medline]
  42. Cariou B, van Harmelen K, Duran-Sandoval D, et al.: The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281:11039–11049, 2006[Abstract/Free Full Text]
  43. Cariou B, van Harmelen K, Duran-Sandoval D, et al.: Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 579:4076–4080, 2005[Medline]
  44. Watanabe M, Houten SM, Mataki C, et al.: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484–489, 2006[Medline]
  45. De Fabiani E, Mitro N, Gilardi F, et al.: Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 278:39124–39132, 2003[Abstract/Free Full Text]
  46. Banba N, Nakamura T, Matsumura M, et al.: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684–690, 2000[Medline]
  47. Utimura R, Fujihara CK, Mattar AL, et al.: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63:209–216, 2003[Medline]
  48. Wada T, Furuichi K, Sakai N, et al.: Up-regulation of monocyte chemo-attractant protein-1 in tubulo-interstitial lesions of human diabetic nephropathy. Kidney Int 58:1492–1499, 2000[Medline]
  49. Dalla Vestra M, Mussap M, Gallina P, et al.: Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16 (Suppl. 1):S78–S82, 2005
  50. Khovidhunkit W, Kim MS, Memon RA, et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:1169–1196, 2004[Abstract/Free Full Text]
  51. Kim MS, Shigenaga J, Moser A, et al.: Repression of farnesoid X receptor during the acute phase response. J Biol Chem 278:8988–8995, 2003[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius III
From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy
Diabetes, June 1, 2008; 57(6): 1439 - 1445.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db06-1642v1
db06-1642v2
56/10/2485    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, T.
Right arrow Articles by Levi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, T.
Right arrow Articles by Levi, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum